Drug
intravenous immune globulin
intravenous immune globulin is a pharmaceutical drug with 5 clinical trials. Historical success rate of 66.7%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_2
1
20%
Ph phase_4
2
40%
Ph not_applicable
1
20%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(2)
Terminated(2)
Other(1)
Detailed Status
Completed2
unknown1
Withdrawn1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
66.7%
Most Advanced
Phase 4
Trials by Phase
Phase 21 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)
Trials by Status
completed240%
unknown120%
withdrawn120%
terminated120%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_4
IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
NCT04033276
completedphase_2
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
NCT04432324
terminatednot_applicable
Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients
NCT00586716
withdrawn
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
NCT00203281
unknownphase_4
Immune Modulation Therapy for Pompe Disease
NCT02525172
Clinical Trials (5)
Showing 5 of 5 trials
NCT04033276Phase 4
IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
NCT04432324Phase 2
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
NCT00586716Not Applicable
Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients
NCT00203281
Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis
NCT02525172Phase 4
Immune Modulation Therapy for Pompe Disease
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5